99.19
price down icon2.76%   -2.82
pre-market  Pre-market:  100.44   1.25   +1.26%
loading
Protagonist Therapeutics Inc stock is traded at $99.19, with a volume of 392.64K. It is down -2.76% in the last 24 hours and down -6.03% over the past month. Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
See More
Previous Close:
$102.01
Open:
$102.01
24h Volume:
392.64K
Relative Volume:
0.54
Market Cap:
$6.38B
Revenue:
$74.06M
Net Income/Loss:
$-114.71M
P/E Ratio:
-54.99
EPS:
-1.8039
Net Cash Flow:
$-117.90M
1W Performance:
-2.93%
1M Performance:
-6.03%
6M Performance:
+16.15%
1Y Performance:
+116.05%
1-Day Range:
Value
$98.89
$102.42
1-Week Range:
Value
$96.69
$104.16
52-Week Range:
Value
$45.14
$107.84

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
Name
Protagonist Therapeutics Inc
Name
Phone
(510) 474-0170
Name
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
Employee
131
Name
Twitter
Name
Next Earnings Date
2026-05-05
Name
Latest SEC Filings
Name
PTGX's Discussions on Twitter

Compare PTGX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PTGX icon
PTGX
Protagonist Therapeutics Inc
99.19 6.56B 74.06M -114.71M -117.90M -1.8039
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
434.52 110.03B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
638.88 67.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
806.46 50.76B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
297.45 40.12B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
151.56 32.68B 742.00K -1.37B -1.07B -7.0731

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-17-25 Initiated Barclays Overweight
Sep-12-25 Initiated Leerink Partners Outperform
Jun-17-25 Initiated Citigroup Buy
Dec-06-24 Initiated BMO Capital Markets Outperform
Dec-06-24 Initiated Goldman Neutral
Nov-05-24 Initiated Wedbush Outperform
Sep-24-24 Initiated TD Cowen Buy
Sep-09-24 Initiated Truist Buy
Oct-30-23 Initiated CapitalOne Overweight
May-25-23 Resumed Jefferies Buy
Aug-25-22 Initiated JMP Securities Mkt Outperform
Feb-11-22 Initiated BTIG Research Buy
Oct-12-21 Upgrade JP Morgan Neutral → Overweight
Oct-11-21 Upgrade Northland Capital Market Perform → Outperform
Sep-20-21 Downgrade JP Morgan Overweight → Neutral
May-24-21 Initiated JMP Securities Mkt Outperform
May-24-21 Initiated Northland Capital Outperform
Jan-06-21 Initiated JP Morgan Overweight
Dec-16-20 Initiated Piper Sandler Overweight
Sep-18-20 Reiterated H.C. Wainwright Buy
Jul-15-20 Initiated Jefferies Buy
May-18-20 Reiterated H.C. Wainwright Buy
Jul-08-19 Initiated H.C. Wainwright Buy
May-09-19 Upgrade Stifel Hold → Buy
Dec-06-18 Initiated Nomura Buy
Jan-29-18 Initiated Stifel Buy
Jul-21-17 Initiated BTIG Research Buy
View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

pulisher
May 22, 2026

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat

May 22, 2026
pulisher
May 21, 2026

Wolfe Research initiates Protagonist Therapeutics stock with outperform rating - Investing.com India

May 21, 2026
pulisher
May 21, 2026

Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com - Investing.com South Africa

May 21, 2026
pulisher
May 21, 2026

Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

May 21, 2026
pulisher
May 21, 2026

PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill

May 21, 2026
pulisher
May 20, 2026

Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN

May 20, 2026
pulisher
May 20, 2026

HC Wainwright Issues Positive Outlook for PTGX Earnings - MarketBeat

May 20, 2026
pulisher
May 20, 2026

Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN

May 20, 2026
pulisher
May 17, 2026

A Look At Protagonist Therapeutics (PTGX) Valuation After First Quarter Earnings Swing To Profit - Sahm

May 17, 2026
pulisher
May 16, 2026

Protagonist Therapeutics, Inc. $PTGX Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat

May 16, 2026
pulisher
May 15, 2026

Protagonist Therapeutics Strengthens Market Buzz On Nasdaq Composite - Kalkine Media

May 15, 2026
pulisher
May 15, 2026

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year - simplywall.st

May 15, 2026
pulisher
May 15, 2026

AIHC Capital Management Ltd Buys New Shares in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

May 15, 2026
pulisher
May 15, 2026

Behavioral Patterns of PTGX and Institutional Flows - Stock Traders Daily

May 15, 2026
pulisher
May 15, 2026

(SEC Amendment) Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo

May 15, 2026
pulisher
May 14, 2026

Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise By Investing.com - Investing.com Australia

May 14, 2026
pulisher
May 14, 2026

Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m after option exercise - Investing.com UK

May 14, 2026
pulisher
May 14, 2026

PTGX (NASDAQ: PTGX) CEO sells 75K shares under 10b5-1 trading plan - Stock Titan

May 14, 2026
pulisher
May 14, 2026

J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $113 - Moomoo

May 14, 2026
pulisher
May 13, 2026

Protagonist Therapeutics Insider Sold Shares Worth $7,509,000, According to a Recent SEC Filing - Moomoo

May 13, 2026
pulisher
May 13, 2026

Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock - Moomoo

May 13, 2026
pulisher
May 12, 2026

Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares - Investing.com Nigeria

May 12, 2026
pulisher
May 12, 2026

Protagonist Therapeutics CEO Dinesh V. Patel sells $7.5m in shares By Investing.com - Investing.com South Africa

May 12, 2026
pulisher
May 12, 2026

Protagonist Therapeutics President, CEO Sold Shares Worth Over $7.5M - TradingView

May 12, 2026
pulisher
May 12, 2026

Protagonist Therapeutics (NASDAQ: PTGX) CEO sells 75,000 shares after exercising options - Stock Titan

May 12, 2026
pulisher
May 12, 2026

75,000-share sale notice filed by PTGX insider (NASDAQ: PTGX) - Stock Titan

May 12, 2026
pulisher
May 12, 2026

State Street Holds 3.12M Protagonist Therapeutics Shares (PTGX) - Stock Titan

May 12, 2026
pulisher
May 12, 2026

Insiders At Protagonist Therapeutics Sold US$11m In Stock, Alluding To Potential Weakness - Moomoo

May 12, 2026
pulisher
May 12, 2026

Protagonist Therapeutics Insider Sold Shares Worth $5,918,880, According to a Recent SEC Filing - Moomoo

May 12, 2026
pulisher
May 12, 2026

Protagonist Therapeutics(PTGX.US) Director Sells US$5.92 Million in Common Stock - Moomoo

May 12, 2026
pulisher
May 11, 2026

Protagonist Therapeutics director Giraudo sells $5.9m in shares By Investing.com - Investing.com Australia

May 11, 2026
pulisher
May 11, 2026

Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 36,000 Shares of Stock - MarketBeat

May 11, 2026
pulisher
May 11, 2026

[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan

May 11, 2026
pulisher
May 11, 2026

Protagonist Therapeutics director Giraudo sells $5.9m in shares - Investing.com

May 11, 2026
pulisher
May 11, 2026

Protagonist Therapeutics Director Sold Shares Worth Over $5.9M - TradingView

May 11, 2026
pulisher
May 11, 2026

BMO reiterates Protagonist Therapeutics stock rating on launch momentum - Investing.com India

May 11, 2026
pulisher
May 11, 2026

BMO reiterates Protagonist Therapeutics stock rating on launch momentum By Investing.com - Investing.com Nigeria

May 11, 2026

Protagonist Therapeutics Inc Stock (PTGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$29.96
price down icon 2.98%
$106.24
price down icon 3.00%
$92.14
price up icon 1.33%
$54.50
price up icon 1.77%
ONC ONC
$310.25
price up icon 0.20%
$151.56
price down icon 1.41%
Cap:     |  Volume (24h):